Swiss National Bank raised its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 57.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,700 shares of the company's stock after buying an additional 37,800 shares during the quarter. Swiss National Bank owned about 0.15% of Replimune Group worth $1,256,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the business. Baker BROS. Advisors LP lifted its stake in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. State Street Corp lifted its position in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares during the last quarter. Geode Capital Management LLC boosted its stake in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock worth $15,657,000 after buying an additional 217,308 shares during the period. Parkman Healthcare Partners LLC increased its position in shares of Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock valued at $8,371,000 after acquiring an additional 238,747 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Replimune Group by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 508,398 shares of the company's stock valued at $6,157,000 after acquiring an additional 23,601 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.
Replimune Group Price Performance
Shares of Replimune Group stock traded up $0.22 on Wednesday, hitting $8.62. The company's stock had a trading volume of 1,436,007 shares, compared to its average volume of 862,062. The firm has a fifty day moving average price of $12.51 and a 200-day moving average price of $12.12. The company has a market capitalization of $663.87 million, a P/E ratio of -2.81 and a beta of 1.30. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Jefferies Financial Group raised their price target on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, BMO Capital Markets increased their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Replimune Group presently has an average rating of "Buy" and an average price target of $19.43.
View Our Latest Report on REPL
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
